OpenEvidence
Overview
OpenEvidence is a cutting-edge AI-driven medical information platform designed to assist healthcare professionals by streamlining clinical decision-making processes. Co-founded by Daniel Nadler and Zachary Ziegler in 2021, the platform leverages AI technology to provide evidence-based medical information sourced from authoritative journals such as The New England Journal of Medicine. Headquartered in Cambridge, Massachusetts, OpenEvidence has rapidly grown in influence, raising over $300 million through multiple funding rounds, the latest being a $210 million investment led by Google Ventures and Kleiner Perkins.
Recent Developments
- July 2025: OpenEvidence secures a $210 million Series B funding round, boosting its valuation to $3.5 billion. The round, co-led by Google Ventures and Kleiner Perkins, positions OpenEvidence as a leader in AI-powered clinical decision support. The platform has now facilitated over 8.5 million consultations each month.
- February 2025: In an expansion move, OpenEvidence announced partnerships with prestigious medical journals such as The New England Journal of Medicine and JAMA, broadening its content library and enhancing its evidence-based decision-making capabilities.
- Early 2025: OpenEvidence launched the DeepConsult AI agent, which enables physicians to conduct advanced medical research autonomously, allowing for the synthesis of extensive medical literature in a fraction of the time.
- July 2024: The application saw rapid growth with 358,000 consultations by logged-in, verified U.S. physicians in one month, which scaled exponentially over the following year.
- Ongoing 2024-2025: Continues to experience significant user adoption, with over 40% of U.S. physicians utilizing the platform daily to inform clinical decisions.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2021 |
| Headquarters | Cambridge, Massachusetts, USA |
| Founders | Daniel Nadler, Zachary Ziegler |
| Revenue | N/A |
| Profits | N/A |
| Key Investors | Google Ventures, Kleiner Perkins, Sequoia Capital, Breyer Capital |
| Industry | Healthcare, Medical Information Technology |
| Number of Employees | 11-50 |
Early History
OpenEvidence began as a project aimed at revolutionizing the way medical professionals access and utilize healthcare information. The idea was conceptualized by Daniel Nadler, leveraging his background as a successful AI entrepreneur with a previous venture, Kensho. Launched during the Mayo Clinic Platform Accelerate program, OpenEvidence was quickly recognized for its potential in organizing global medical knowledge using AI. By focusing on critical healthcare insights and partnering with prestigious medical publications, the platform addressed the pressing need for timely, accurate medical information amid growing data complexities.
Company Profile and Achievements
OpenEvidence operates by integrating robust AI with medical data from over 35 million peer-reviewed publications. This provides healthcare professionals direct, evidence-based answers at the point of care, significantly reducing lag times between research publication and clinical application. The platform's significant milestones include:
- Strategic Partnerships: Securing partnerships with leading medical journals such as NEJM and JAMA, enhancing the depth and reliability of its content.
- AI Innovation: Introduction of DeepConsult, an AI-powered agent facilitating complex query responses autonomously.
- Market Penetration: Achieving widespread adoption, with significant traction amongst clinicians due to its user-friendliness and reliability.
- Supported 8.5 million monthly clinical consultations, demonstrating potential to influence patient outcomes on a national scale.
Current Operations and Market Position
OpenEvidence continues to expand its capabilities within the healthcare sector, focusing on enhancing its AI-driven clinical decision support systems. The platform is widely used across thousands of U.S. medical centers, addressing the challenge of physician burnout by streamlining access to relevant medical research. Its competitive advantage lies in its robust data partnerships and ability to deliver precise, evidence-based information to physicians swiftly, enhancing decision-making and patient care.
Conclusion
OpenEvidence represents a transformative evolution in healthcare technology, harnessing AI to improve the efficiency and effectiveness of clinical decision-making. With substantial funding and backing from some of the tech and healthcare industry's most notable investors, OpenEvidence is poised to redefine standards in evidence-based medicine. The platform's ongoing development of advanced AI features, such as DeepConsult, further positions it to play a critical role in addressing the complexities of modern healthcare, offering immense potential benefits for both physicians and patients globally.